Healthcare AI governance works best when one framework organizes the program and specialized guidance supplies the clinical, regulatory, and monitoring detail.
A healthcare AI governance framework should help a health system answer four questions: what AI it uses, what can go wrong, who owns each decision, and what evidence shows the system remains safe and useful. No single framework answers every clinical, technical, regulatory, and operational question. The practical move is to choose one organizing structure and layer specialized guidance onto it.
NIST AI RMF can organize the risk process. CHAI adds health-specific assurance language. Joint Commission guidance connects responsible use to healthcare governance and quality. ACR guidance adds imaging-specific acceptance testing and monitoring. FDA requirements apply when the product is a regulated medical device.
Generative AI medical device risk assessment should connect clinical consequence, output variability, autonomy, human review, foundation model dependencies, and workflow controls.
AI governance in healthcare is how an organization decides which AI tools enter care, on what evidence, under whose ownership, and with what monitoring. This is the practical structure most health systems build.
Clinical AI governance is usually discussed at the model, vendor, and workflow levels. But hospitals also need to govern the infrastructure below the application layer: data locality, uptime, access, logs, monitoring, recovery, and system change.
A clinical AI governance framework gives hospitals a way to review, deploy, monitor, and retire AI tools with clear accountability. The goal is not bureaucracy for its own sake, but safer decisions around risk, evidence, privacy, workflow, vendor management, and ongoing oversight.
| Framework or authority | Best use | What it adds | What it does not replace |
|---|---|---|---|
| NIST AI RMF | Program structure | Govern, map, measure, and manage across the AI lifecycle | Clinical evidence or medical-device review |
| CHAI | Health AI assurance | Healthcare terminology, model information, testing, and assurance practices | Local accountability and workflow validation |
| Joint Commission | Responsible use in healthcare organizations | Governance, policies, data use, validation, monitoring, transparency, and safety expectations | Product-specific evidence and specialty guidance |
| ACR practice parameter and Assess-AI | Medical imaging AI | Selection, acceptance testing, workflow, monitoring, and real-world data collection | Enterprise governance outside imaging |
| FDA device requirements | Regulated AI-enabled products | Intended use, premarket review, labeling, modifications, and lifecycle controls | Local procurement, implementation, and outcome monitoring |
| AHRQ and specialty guidance | Use-case detail | Safety evidence, workflow lessons, and specialty-specific expectations | A system-wide governance structure |
A framework should not be selected because it is popular or broad. Select it because it organizes the decisions the health system must make. NIST is a strong base when the organization needs one risk language across clinical and nonclinical AI. A health-specific framework becomes more important when clinical evidence, patient safety, and care delivery are central. Specialty guidance should control the details where clinical practice differs.
Regulation sits beside governance rather than underneath it. FDA authorization answers a product and intended-use question. It does not tell a hospital whether the tool fits local patients, interfaces, staffing, or escalation rules.
A framework becomes useful when every principle produces an artifact that a reviewer can inspect. A policy statement without evidence is not an operating control.
Frameworks often describe what should happen without deciding who has authority. The local program should name the group that accepts risk, the clinical owner, the technical owner, privacy and security reviewers, the monitoring owner, and the person who can pause use when evidence changes.
High-risk systems should not be approved through an informal chain of separate reviews.
The final decision should show:
A scheduling assistant and a diagnostic recommendation system should not receive the same review. Risk tiers can consider clinical influence, autonomy, patient impact, reversibility, data sensitivity, user ability to review the output, and how quickly harm could spread.
The tier should control the depth of evidence review, local testing, monitoring, executive approval, and re-review after a change. It should not become a shortcut that lets low-risk tools disappear from the inventory.